Cart
sales@molnova.com
SMER-28
CAS No. 307538-42-7
SMER-28( SMER28 )
Catalog No. M13983 CAS No. 307538-42-7
A small-molecule enhancer/inducer of Autophagy; decreases the levels of Aβ peptide (EC50=10 uM) and APP-CTF (EC50 of 20 uM) in a γ-secretase-independent manner in primary neuronal cultures, Atg5, Beclin1 and Ulk1 are shown to be involved in the degradation of Aβ and APP-CTF.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 45 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 43 | In Stock |
|
| 10MG | 64 | In Stock |
|
| 25MG | 123 | In Stock |
|
| 50MG | 226 | In Stock |
|
| 100MG | 365 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSMER-28
-
NoteResearch use only, not for human use.
-
Brief DescriptionA small-molecule enhancer/inducer of Autophagy; decreases the levels of Aβ peptide (EC50=10 uM) and APP-CTF (EC50 of 20 uM) in a γ-secretase-independent manner in primary neuronal cultures, Atg5, Beclin1 and Ulk1 are shown to be involved in the degradation of Aβ and APP-CTF.
-
DescriptionA small-molecule enhancer/inducer of Autophagy; decreases the levels of Aβ peptide (EC50=10 uM) and APP-CTF (EC50 of 20 uM) in a γ-secretase-independent manner in primary neuronal cultures, Atg5, Beclin1 and Ulk1 are shown to be involved in the degradation of Aβ and APP-CTF; enhances erythropoiesis in a range of in vitro and in vivo models of DBA, and protects against neurodegeneration in Drosophila model of Huntington’s disease.
-
In VitroSMER28 (5-200 μM; 24 hours) shows a dose dependent decline of cell viability. Cell Viability Assay Cell Line:MMS1 cells Concentration:5, 25, 50, 75, 100, 150, 200 μM Incubation Time:24 hours Result:Showed a dose dependent decline of cell viability.
-
In VivoSMER28 (15-65 mg/kg; i.h.; daily, two days before irradiation and during the three days of irradiation) significantly protects against post-irradiation weight loss and enhances survival of mice at 65 mg/kg. Animal Model:14 to 16 weeks male mice (Balb/c)Dosage:15, 65 mg/kg Administration:Subcutaneous injection; two days before irradiation and during the three days of irradiation (total 5 days)Result:Significantly protected against post-irradiation weight loss and enhanced survival of mice at 65 mg/kg.
-
SynonymsSMER28
-
PathwayAutophagy
-
TargetAutophagy
-
RecptorAutophagy
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number307538-42-7
-
Formula Weight264.1212
-
Molecular FormulaC11H10BrN3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESC=CCNC1=C2C=C(Br)C=CC2=NC=N1
-
Chemical Name4-Quinazolinamine, 6-bromo-N-2-propen-1-yl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
ULK1-IN-2
ULK1-IN-2 is a potent ULK1 inhibitor with potential anticancer activity, inducing apoptosis while blocking autophagy.
-
LYN-1604 2HCl 221675...
LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604, to be the best candidate for a ULK1 agonist.?LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo.
-
PHY34
PHY34 is a potent autophagy inhibitor with cytotoxic effects by inhibiting autophagy at a late stage (MDA-MB-435 IC50=23 nM, MDA-MB-231 IC50=5.2 nM); disrupts lysosomal function, significantly inhibits the growth of cancer cell lines in hollow fibers.
